Condition
Liver Fibrosis
Liver fibrosis is a buildup of scar tissue in the liver, which happens when long-term injury or inflammation switches on stellate cells that lay down too much of the fibrous material between liver cells. Among supplements, TB-500, a synthetic version of a thymosin beta 4 fragment, has the most to show so far, and lab models found it calmed those stellate cells and reduced scar-tissue buildup. The evidence is limited, though, because the work was mostly in animals or cell studies, so it says little yet about what happens in people.
Sources: PMID 26006229; PMID 34280397
- Updated
- How we grade
- 5 studies cited
- Supplements studied
- 0
- Medicines and peptides
- 1
- Graded outcomes
- 1
Prescription medicines and peptides studied, for context
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Liver Fibrosis Protection Regulates hepatic stellate cell activation. Reduces extracellular matrix deposition. Anti-fibrotic effects demonstrated in preclinical liver injury models. | Improves (the measure goes down) | Moderate effect | 5 studies | 60 people | ||
Studies that measured liver fibrosis protection
| ||||||
Key findings
- Liver Fibrosis ProtectionImproves (the measure goes down)
Studies cited
5 studies from PubMed
- Thymosin β(4) and β(10) Expression in Human Organs during Development: A Review.
- Targeted Deletion of Thymosin Beta 4 in Hepatic Stellate Cells Ameliorates Liver Fibrosis in a Transgenic Mouse Model
- Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4
- Thymosin Beta 4 Is a Potential Regulator of Hepatic Stellate Cells
- Potential role of thymosin Beta 4 in liver fibrosis